Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 14, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$11.5B
sum of reported positions
Reported positions
84
Changes vs prior quarter
51
17 new · 18 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 63 measured positions in 8 quarters, the typical new or larger position finished −2.9 pts against the S&P 500 and 44% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
| Company | Shares | Value | Weight |
|---|---|---|---|
| 10.3M | $2.74B | 23.8% | |
| 28.9M | $792M | 6.9% | |
| 6.67M | $740M | 6.4% | |
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $9.44B | $11.5B |
| Positions | 85 | 84 |
| Biggest line | — | Ascendis Pharma A 24% |
| 11.5M |
| $667M |
| 5.8% |
| 9.91M | $436M | 3.8% |
| 12.2M | $390M | 3.4% |
| 8.39M | $341M | 3.0% |
| 9.55M | $324M | 2.8% |
| 7.81M | $287M | 2.5% |
| 7M | $234M | 2.0% |
| 7.26M | $215M | 1.9% |
| 7.69M | $208M | 1.8% |
| 7.64M | $205M | 1.8% |
| 2.45M | $179M | 1.6% |
| 8.02M | $179M | 1.6% |
| 18M | $174M | 1.5% |
| 11.2M | $172M | 1.5% |
| 23.6M | $160M | 1.4% |
| 15.8M | $158M | 1.4% |
WAVE LIFE SCIENCES LTD | 27M | $157M | 1.4% |
NUVALENT INC-A | 1.25M | $154M | 1.3% |
| 1.13M | $151M | 1.3% |
| 1.55M | $148M | 1.3% |
| 11.3M | $147M | 1.3% |
| 12M | $120M | 1.0% |
Ascendis Pharma A (ASND)
10.3M shares
Parabilis Medicines (PBLS)
28.9M shares
Edgewise Therapeutics (EWTX)
10.4M → 8.39M shares (−20%)
Hemab Therapeutics Holdings (COAG)
7.81M shares
Artiva Biotherapeutics (ARTV)
9.85M → 18M shares (+82%)
Abivax (ABVX)
1.13M shares
Oruka Therapeutics (ORKA)
1.55M shares
Solid Biosciences (SLDB)
9.34M → 12M shares (+29%)
Xencor Inc (XNCR)
4.9M → 5.27M shares (+8%)
Intellia Therapeutics (NTLA)
4.53M shares
Definium Therapeutics (DFTX)
1.5M shares
Aclaris Therapeutics (ACRS)
6.8M → 12.7M shares (+87%)
Sana Biotechnology (SANA)
18.8M shares
Geron (GERN)
63.8M → 42.8M shares (−33%)
Rezolute (RZLT)
9.18M → 9.45M shares (+3%)
Vor Biopharma (VOR)
5.4M → 2.4M shares (−56%)
Aktis Oncology (AKTS)
1.5M → 1.31M shares (−13%)
Bioage Labs (BIOA)
1.65M → 1.67M shares (+1%)
Prelude Therapeutics (PRLD)
6.48M shares
Q32 Bio (QTTB)
2.33M shares
Editas Medicine (EDIT)
8.89M shares
Ovid Therapeutics (OVID)
10.7M → 10.5M shares (−2%)
Acrivon Therapeutics (ACRV)
8.34M → 12.2M shares (+47%)
Altimmune (ALT)
6.5M shares
Avalo Therapeutics (AVTX)
663K → 1M shares (+51%)
